
Blood-Borne Diseases
Latest News
Latest Videos

CME Content
More News

As of June 1, there have been at least 6 cases of Ebola detected in Mbandaka, a port city with a population of more than 1.2 million people.

Investigators detailed a promising new approach to fighting malaria with an antibody that targets a specific malaria protein, triggering the pathogen to self-destruct.

A new case of Ebola has been confirmed in the city of Beni in the Democratic Republic of the Congo.

How has treating infections changed with the availability of experimental vaccines and therapeutics, and how can we apply this to COVID-19 today?

How does sharing needles impact the risk for hepatitis C among people who inject drugs?

The last confirmed patient with Ebola was discharged from care on March 4, 2020.

To assess available evidence and provide an update from the 2013 review, a team of investigators reviewed more than 80 studies featuring data from over 179,000 individuals.

PWID are unlikely to receive testing for HIV and hepatitis C, according to a new study that found that 8.5% were tested for HIV and 7.7% were tested for HCV within 1 year of a clinical encounter consistent with injection drug use.

The International Health Regulations Emergency Committee decided today that the Ebola outbreak in the Democratic Republic of the Congo remains a PHEIC.

A new article examines pregnancy outcomes among women who received the rVSV-ZEBOV vaccine in the STRIVE study.

Despite new treatment options with a lower theoretical risk, approximately 40% of patients with HCV experienced a drug-drug interaction.

Andrea L. Cox, MD, PhD, comments on the future of HCV vaccine development efforts in light of the 2019 trial which did not prevent chronic infection.

In this episode, our guests compare the West African Ebola outbreak to the ongoing outbreak in the Democratic Republic of the Congo.

Andrea L. Cox, MD, PhD, discusses some of the challenges in developing a vaccine for hepatitis C and details the results of a vaccine trial.

Investigators of a new analysis detail how Ebola case definitions became increasingly complex and discordant during the 6-month period in the countries surrounding the DRC.

A literature meta-analysis determined the worldwide prevalence of hepatitis B virus in people living with HIV.

Ervebo has been approved for the prevention of Ebola virus disease, caused by Zaire ebolavirus in individuals 18 years of age and older.

Ebola vaccines could be given as an emergency intervention to individuals exposed to the virus.

Observations about the body’s response to malaria infection can lead to new treatments for HIV and lupus, investigators believe.

An epidemiologist explores the changing epidemiology of a familiar disease.

The PALM trial evaluated the safety and efficacy of several experimental treatments for Ebola in the Democratic Republic of Congo.

TAF causes cholesterol levels to rise, but that includes levels of “good cholesterol” HDL. Researchers concluded that there is no significant difference in cardiovascular risk profiles between people taking TAF and those taking TDF.

Investigators now think that Ebola prevention methods should be a top priority moving forward.

Prequalification status indicates that the vaccine meets the WHO’s standard for efficacy, safety, and quality.

Since 2014 NYC Health + Hospitals has worked to maintain preparedness against diseases like Ebola.






































































































